To date, no study evaluates the effect of atherosclerosis risk level on the efficacy of BPH drug therapies. Therefore, the present study aimed to assess the effect of atherosclerosis risk levels on the effectiveness of Tamsulosin and Tadalafil in LUTS treatment.
The present study was a randomized clinical trial that assessed men with LUTS symptoms (at least six months). The inclusion criteria were being older than 50 years, international prostate symptom score (IPSS) ≥ 13, and maximum urinary flow rate (Qmax) between 4 and 15 ml/s. Framingham Risk Score was used to measure atherosclerosis risk. The patients were classified into four groups, including group 1: Patients with low risk and treated with Tamsulosin (0.4 mg/day), group 2: Patients with low risk and treated with Tadalafil (5 mg/day), group 3: Patients with high risk and treated with Tamsulosin (0.4 mg/day), group 4: Patients with high risk and treated with Tadalafil (5 mg/day).
The study included 44 and 38 patients receiving Tamsulosin and Tadalafil, respectively. The means (SD) of the baseline age for the Tamsulosin and Tadalafil groups were equal to 60.6 (6.8) and 58.8 (6.7), respectively (p-value = 0.213). The models revealed no impact of the atherosclerosis risk level on the drugs' effects (p-values = 0.378, 0.975, 0.743 for IPSS, QMAX, and VOID, respectively).
The present study's findings could not show the impact of atherosclerosis risk levels on the efficiency of Tamsolusin and Tadalafil in men with LUTS.
Annals of medicine and surgery (2012). 2022 Jul 09*** epublish ***
Ali Tavoosian, Leonardo Oliveira Reis, Pavan Aluru, Alireza Khajavi, Seyed Mohammad Kazem Aghamir
Urology Research Center, Tehran University of Medical Sciences, Tehran, Iran., UroScience and Department of Surgery (Urology), School of Medical Sciences, University of Campinas, Unicamp, Pontifical Catholic University of Campinas, PUC-Campinas, Campinas, São Paulo, Brazil., Department of Urology, Sunderland Royal Hospital, UK., Faculty of Paramedical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.